Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may be quite potent in halting disease progression in certain patients. Their findings were published in Clinical Cancer Research (doi:10.1158/1078-0432.CCR-15-1762).
Publications
Scientific Journals for January 2016
Ophthalmology BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma Presented at: European Association for Vision and Eye Research Annual Meeting October 2014, Nice, France; and International Society of Ocular Oncology…
Read More Opdivo Plus Yervoy Gets FDA OK for Melanoma
WASHINGTON — Indications for the blockbuster cancer drug nivolumab (Opdivo) have expanded again, as the FDA has approved the anti-PD-1 antibody in combination with ipilimumab (Yervoy) for treatment of unresectable or metastatic melanoma.
FDA expands approval of Opdivo plus Yervoy for melanoma
The FDA expanded the approval of nivolumab plus ipilimumab to include all patients with unresectable or metastatic melanoma, regardless of BRAF V600 mutational status.